Suvretta Capital Management »

Arrivent Biopharma shares owned by Suvretta Capital Management

Quarter-by-quarter ownership of Arrivent Biopharma shares owned by Suvretta Capital Management from 13F filings

Historical chart of Suvretta Capital Management investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Suvretta Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $28M 1.6M 17.86

More positions owned by Suvretta Capital Management

Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Biohaven (BHVN)
Kura Oncology (KURA)
Arcellx Common Stock (ACLX)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Meta Platforms Cl A (META)
Ultragenyx Pharmaceutical (RARE)
Arcutis Biotherapeutics (ARQT)
Eyepoint Pharmaceuticals Com New (EYPT)
89bio (ETNB)
Royalty Pharma Shs Class A (RPRX)
Intra Cellular Therapies (ITCI)
Amazon (AMZN)
Advanced Micro Devices (AMD)
Insmed Com Par $.01 (INSM)

View all positions for Suvretta Capital Management

Top funds holding Arrivent Biopharma

OrbiMed Advisors
FMR
Octagon Capital Advisors
Sofinnova Ventures
Suvretta Capital Management
General Catalyst Group Management
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Citadel Advisors
Geode Capital Management
Millennium Management
Farallon Capital Management

View all funds holding Arrivent Biopharma